Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for NASDAQ:SHPGY
193.49
+0.03 (0.02%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 191.62 - 193.87
52 week 147.60 - 270.63
Open 192.29
Vol / Avg. 0.00/2.15M
Mkt cap 58.46B
P/E 28.68
Div/yield 0.66/0.70
EPS 6.75
Shares 610.30M
Beta 1.05
Inst. own 10%
Aug 2, 2016
Q2 2016 Shire PLC Earnings Call - 9:00AM EDT - Add to calendar
Aug 2, 2016
Q2 2016 Shire PLC Earnings Release - 7:00AM EDT - Add to calendar
Jun 9, 2016
Shire PLC at Jefferies Healthcare Conference
Jun 8, 2016
Shire PLC at Goldman Sachs Global Healthcare Conference
May 27, 2016
Shire PLC Ordinary Shareholders Meeting
May 4, 2016
Shire PLC at Deutsche Bank Health Care Conference
Apr 29, 2016
Q1 2016 Shire PLC Earnings Call
Apr 29, 2016
Q1 2016 Shire PLC Earnings Release
Apr 28, 2016
Shire PLC Annual Shareholders Meeting
Apr 27, 2016
Shire PLC Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 23.96% 20.88%
Operating margin 31.82% 22.12%
EBITD margin - 44.15%
Return on average assets 8.08% 8.86%
Return on average equity 16.32% 14.47%
Employees 5,548 -
CDP Score - 91 B

Address

5 Riverwalk Citywest Business Campus, Dublin 24
DUBLIN,
Ireland
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Bio & Compensation  - Reuters
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Bio & Compensation  - Reuters
Ginger Gregory Chief Human Resource Officer
Bio & Compensation  - Reuters
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 52
Bio & Compensation  - Reuters
Phil J. Vickers Head of Research and Development
Age: 55
Bio & Compensation  - Reuters
Oliver Strawbridge Senior Assistant Company Secretary
Bio & Compensation  - Reuters
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Olivier Bohuon Non-Executive Director
Age: 56
Bio & Compensation  - Reuters
Gail D. Fosler Non-Executive Director
Age: 68
Bio & Compensation  - Reuters
Sara Mathew Non-Executive Director
Age: 60
Bio & Compensation  - Reuters